搜索
再生元制药
REGN添加自选
618.030USD
+5.530+0.90%
收盘 06/23, 16:00（美东）报价延迟15分钟
64.79B总市值
14.55市盈率 TTM
关键数据
607.920今开
621.790最高
1.28M成交量
14.55市盈率 TTM
10.94市盈率动
3.580股息TTM
1.22%换手率
612.500昨收
607.920最低
664.30M成交额
14.71市盈率静
2.07市净率
0.58%股息率 TTM
11.40%ROA
821.11052周最高
0.87量比
4.41B净利润
105.00M总股本
42.4810每股收益TTM
0.26Beta
14.69%ROE
476.48752周最低
2.26%振幅
81.43%毛利率
64.79B总市值
-2.37回报/风险
1.74%风险率
TradingKey 再生元制药股票评分
单位: USD 更新时间: 2026-06-23操作建议
再生元制药当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名19/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价830.43。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
再生元制药评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
40°C
过冷
过热
中性
再生元制药亮点
亮点风险
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
估值低估
公司最新PE估值14.55，处于3年历史低位
机构减仓
最新机构持股94.67M股，环比减少1.74%
梅森·霍金斯持仓
明星投资者梅森·霍金斯持仓，最新持仓市值160.58K
活跃度增加
近期活跃度增加，过去20天平均换手率0.33
分析师目标
根据
32
位分析师
买入
评级
830.429
目标均价
+35.58%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
再生元制药新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
再生元制药简介
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
公司代码REGN
公司再生元制药
CEOSchleifer (Leonard S)
网址https://www.regeneron.com/
相关品种
热门品种
常见问题
再生元制药(REGN)的当前股价是多少？
再生元制药(REGN)的当前股价是 618.03。
再生元制药的股票代码是什么？
再生元制药的股票代码是REGN。
再生元制药股票的52周最高点是多少？
再生元制药股票的52周最高点是821.11。
再生元制药股票的52周最低点是多少？
再生元制药股票的52周最低点是476.49。
再生元制药的市值是多少？
再生元制药的市值是64.89B。
现在再生元制药(REGN)的股票是买入、持有还是卖出？
根据分析师评级，再生元制药(REGN)的总体评级为买入，目标价格为830.43。
再生元制药(REGN)股票的每股收益（EPS TTM）是多少
再生元制药(REGN)股票的每股收益（EPS TTM）是43.07。
